Skip to content

National Cancer Institute selects Kaiser Permanente for new Cancer Screening Research Network

Kaiser Permanente Northern California will play leading role in national study to identify impact of new multi-cancer detection tests

The National Cancer Institute (NCI), part of the National Institutes of Health, today announced that it has selected Kaiser Permanente Northern California (KPNC) as one of the institutions that will help launch a new national clinical trials network to evaluate emerging technologies for cancer screening, with the goal of reducing cancer-related illnesses and deaths.

The Cancer Screening Research Network (CSRN) will support the Biden-Harris Administration’s Cancer MoonshotSM by investigating how to identify cancers earlier, when they may be easier to treat. KPNC will serve as one of 7 funded CSRN Accrual, Enrollment, and Screening Site (ACCESS) Hubs that will lead efforts to enroll participants in their geographic and coverage areas. Researchers at Kaiser Permanente Southern California (KPSC) and the Kaiser Permanente School of Medicine (KPSOM) have partnered with KPNC to establish its ACCESS Hub.

Jeffrey K. Lee, MD, MPH

“It’s a tremendous honor for KPNC to be selected as part of the NCI Cancer Screening Research Network initiative and a testimony to our outstanding integrated health care system and Division of Research that allows us to conduct impactful cancer screening trials for the benefit of our members and beyond,” said Jeffrey K. Lee, MD, MPH, a research scientist at the Kaiser Permanente Division of Research (DOR) and a gastroenterologist with The Permanente Medical Group.

Lee will co-lead the KPNC CSRN site with DOR research scientists Lori C. Sakoda, PhD, and Douglas A. Corley, MD, PhD.

Additional partners include Bechien Wu, MD, MPH, a gastroenterologist with the KPSC Department of Research & Evaluation, and Quyen-Ngo Metzger, MD, MPH, a professor at KPSOM.

The CSRN will conduct rigorous multicenter cancer screening trials and studies with large and diverse populations in a variety of health care settings that evaluate strategies and approaches for risk-based screening and emerging cancer screening modalities. Data collected through these clinical trials can be used to develop evidence-based guidelines for cancer screening.

Tracy Lieu, MD, MPH

“The Division of Research is proud to be included in this national effort to understand the effectiveness of multi-cancer detection assays,” said DOR Director Tracy Lieu, MD, MPH. “Kaiser Permanente has always been a leader in cancer screening and prevention, and this study aligns with our mission to provide patients with the best possible care.”

The first CSRN study will study the effectiveness of multi-cancer detection assays. These tests measure biological signals in body fluids that may be shed by cancer cells from a number of cancer types. There are a number of tests in development to screen for cancers from different organ sites at the same time.

“NCI has launched CSRN to evaluate a variety of different technologies for the purpose of cancer screening,” said Lori M. Minasian, MD, deputy director of NCI’s Division of Cancer Prevention. “Detecting cancer early is not enough to improve people’s lives. Through CSRN, we’re going to study whether using these new technologies will make a difference in people’s lives.”

There remain many unanswered questions about if and how multi-cancer detection assays will improve cancer screening or reduce cancer deaths. Researchers are also interested in learning the emotional and economic impact of test results, their potential to lead to unnecessary invasive procedures, and whether people will stop following current cancer screening guidelines if they receive a negative test result. It is also not known if these blood tests will make screening more accessible, exacerbate disparities, or lead to overdiagnosis and treatment of cancers that might have gone away on their own or not caused harm.

The 6 other funded ACCESS Hubs are:

  • Henry Ford Health + Michigan State University Health Sciences
  • OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
  • University of Colorado Cancer Center
  • University of North Carolina Lineberger Comprehensive Cancer Center
  • Virginia Commonwealth University, Inova, and Sentara Health
  • Washington University School of Medicine in St. Louis

The Department of Defense and the Veteran’s Health Systems will also participate as ACCESS Hubs funded by their respective agencies. Fred Hutchinson Cancer Center in Seattle will serve as both the Coordinating and Communications Center and the Statistics and Data Management Center.

# # #

About the Kaiser Permanente Division of Research

The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. It seeks to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 600-plus staff is working on more than 450 epidemiological and health services research projects. For more information, visit or follow us @KPDOR.


This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top